Information Provided By:
Fly News Breaks for May 21, 2019
REGN
May 21, 2019 | 05:07 EDT
Piper Jaffray analyst Christopher Raymond says he's increasingly confident in his Street-high Dupixent estimates following his firm's latest dermatologist survey. The survey indicated "steepening use trends" for Regeneron Pharmaceuticals' Dupixent and a "meaningful inflection" in use for atopic dermatitis, Raymond tells investors in a research note. Further, the feedback suggests that the new adolescent atopic dermatitis label is already driving "meaningful growth as well as continued acceleration," adds the analyst. He recommends buying shares of Regeneron at current levels and keeps an Overweight rating on the name with a $435 price target.
News For REGN From the Last 2 Days
There are no results for your query REGN